Indole derivative compounds acting as ferroptosis inhibitors have been reported in a Mitoimmune Therapeutics Inc. patent as potentially useful for the treatment of neurodegeneration, diabetes, stroke, myocardial infarction, liver, lung diseases, eye, renal disorders, among others.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have patented N-acylhydrazone compounds acting as sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers which are described as being potentially useful for the treatment of pain.
Tevard Biosciences Inc. has entered into a 4-year global research collaboration with Vertex Pharmaceuticals Inc. aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD) caused by nonsense mutations, with options to expand into additional muscular dystrophies and a second indication.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders.
Jiangsu Nhwa Pharmaceutical Co. Ltd. and Shujing Biopharma Co. Ltd. have synthesized oxaspiro derivatives acting as μ-opioid receptor agonists reported to be useful for the treatment of pain.
Previous research has suggested that neurons in multiple sclerosis (MS) exhibit metabolic exhaustion, believed to be caused by chronic hyperexcitability, which can lead to neurodegeneration. Researchers from Heidelberg University and affiliated organizations aimed to investigate the role of nodal Kv7 (outward rectifying) and perinodal oligodendroglial Kir4.1 (inward rectifying) channels as potential therapeutic targets for neuroprotection through balancing of neuronal excitability caused by inflammatory demyelination.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have synthesized N-acylhydrazone acting as sodium channel protein type 9 subunit alpha (SCN9A, Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
RSS
